Evidence map›Paper›PMID 38959848›Full record

ArticleEBioMedicine2024

Identification of disease phenotypes in acetylcholine receptor-antibody myasthenia gravis using proteomics-based consensus clustering.

Christopher Nelke, Christina B Schroeter, Sumanta Barman, Frauke Stascheit, Lars Masanneck, Lukas Theissen, Niklas Huntemann, Sara Walli, Derya Cengiz, Vera Dobelmann and 11 more

Abstract read
In one paragraph

Article in EBioMedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Christopher NelkeDepartment of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany.
Christina B SchroeterDepartment of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany.
Sumanta BarmanDepartment of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany.
Frauke StascheitDepartment of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Lars MasanneckDepartment of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany.
Lukas TheissenDepartment of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany.
Niklas HuntemannDepartment of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany.
Sara WalliDepartment of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany.
Derya CengizDepartment of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany.
Vera DobelmannDepartment of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany.
Anna VogelsangDepartment of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany.
Marc PawlitzkiDepartment of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany.
Saskia RäuberDepartment of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany.
Felix F KonenDepartment of Neurology, Hannover Medical School, Hannover, Germany.
Thomas SkripuletzDepartment of Neurology, Hannover Medical School, Hannover, Germany.
Hans-Peter HartungDepartment of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany; Brain and Mind Center, University of Sydney, Sydney NSW, Australia; Department of Neurology, Palacky University Olomouc, Olomouc, Czech Republic.
Simone KönigCore Unit Proteomics, Interdisciplinary Center for Clinical Research, Medical Faculty, University of Münster, Münster, Germany.
Andreas RoosDepartment of Neuropaediatrics, Neuromuscular Centre, Universitätsmedizin Essen, Essen, Germany.
Andreas MeiselDepartment of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Sven G MeuthDepartment of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany.
Tobias RuckDepartment of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany. Electronic address: Tobias.Ruck@med.uni-duesseldorf.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe clinical heterogeneity of myasthenia gravis (MG), an autoimmune disease defined by antibodies (Ab) directed against the postsynaptic membrane, constitutes a challenge for patient stratification and treatment decision making. Novel strategies are needed to classify patients based on their biological phenotypes aiming to improve patient selection and treatment outcomes.

methodsFor this purpose, we assessed the serum proteome of a cohort of 140 patients with anti-acetylcholine receptor-Ab-positive MG and utilised consensus clustering as an unsupervised tool to assign patients to biological profiles. For in-depth analysis, we used immunogenomic sequencing to study the B cell repertoire of a subgroup of patients and an in vitro assay using primary human muscle cells to interrogate serum-induced complement formation.

findingsThis strategy identified four distinct patient phenotypes based on their proteomic patterns in their serum. Notably, one patient phenotype, here named PS3, was characterised by high disease severity and complement activation as defining features. Assessing a subgroup of patients, hyperexpanded antibody clones were present in the B cell repertoire of the PS3 group and effectively activated complement as compared to other patients. In line with their disease phenotype, PS3 patients were more likely to benefit from complement-inhibiting therapies. These findings were validated in a prospective cohort of 18 patients using a cell-based assay.

interpretationCollectively, this study suggests proteomics-based clustering as a gateway to assign patients to a biological signature likely to benefit from complement inhibition and provides a stratification strategy for clinical practice.

fundingCN and CBS were supported by the Forschungskommission of the Medical Faculty of the Heinrich Heine University Düsseldorf. CN was supported by the Else Kröner-Fresenius-Stiftung (EKEA.38). CBS was supported by the Deutsche Forschungsgemeinschaft (DFG-German Research Foundation) with a Walter Benjamin fellowship (project 539363086). The project was supported by the Ministry of Culture and Science of North Rhine-Westphalia (MODS, "Profilbildung 2020" [grant no. PROFILNRW-2020-107-A]).

Indexed as

AutoantibodiesMyasthenia GravisPhenotypeProteomicsReceptors, CholinergicAdultAgedB-LymphocytesCluster AnalysisComplement ActivationFemaleHumansMaleMiddle AgedProteomeAutoantibodiesProteomeReceptors, CholinergicComplementComplement inhibitionConsensus clusteringMyasthenia gravisProteomics

Identifiers

PMID38959848
PMCPMC11269806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.